Last reviewed · How we verify
NCT04822025
A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults
Phase 2 trial testing MVC-COV1901 (High-Dose) in Covid19 Vaccine in 420 participants. Completed in 28 January 2022.
25 August 2021
Quick facts
| Lead sponsor | Medigen Vaccine Biologics Corp. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 420 |
| Start date | 20 May 2021 |
| Primary completion | 25 August 2021 |
| Estimated completion | 28 January 2022 |
| Sites | 4 locations across Taiwan |
Drugs / interventions tested
- MVC-COV1901 (High-Dose) — full drug profile →
- MVC-COV1901(Mid-Dose) — full drug profile →
Conditions studied
- Covid19 Vaccine — all drugs for Covid19 Vaccine →
Sponsor
Medigen Vaccine Biologics Corp. — full company profile →
Who can join
65 and older, any sex, with Covid19 Vaccine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess the safety and immunogenicity of MVC-COV1901 vaccine in two different dose forms in participants who are generally healthy or with stable pre-existing health conditions.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Efficacy and safety of COVID-19 vaccines.
Graña C, Ghosn L, Evrenoglou T, Jarde A, et al · · 2022 · cited 227× · PMID 36473651 · DOI 10.1002/14651858.cd015477 -
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial.
Waits A, Chen JY, Cheng WH, Yeh JI, et al · · 2022 · cited 6× · PMID 36049700 · DOI 10.1016/j.ijid.2022.08.021 -
Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment.
Bandaru R, Rout SR, Kamble OS, Samal SK, et al · · 2022 · cited 4× · PMID 35437418 · DOI 10.1016/j.procbio.2022.04.011
Verify or expand the search:
- PubMed search for NCT04822025
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Medigen Vaccine Biologics Corp. trials
Trials by the same sponsor.
- NCT07178522 — A Study to Evaluate the Immunogenicity and Safety of an EV71 Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compare · Phase 3 · recruiting
- NCT05198596 — A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above · Phase 3 · completed
- NCT05426343 — A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222 · Phase 3 · completed
- NCT05216601 — A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19 · Phase 1 · completed
- NCT05197153 — A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19 · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04822025 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medigen Vaccine Biologics Corp.
- Last refreshed: 28 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04822025.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing